Related references
Note: Only part of the references are listed.Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
Clive G. Ballard et al.
PARKINSONISM & RELATED DISORDERS (2020)
Psychosis in Parkinson's disease: identification, prevention and treatment
Johannes Levin et al.
JOURNAL OF NEURAL TRANSMISSION (2016)
The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease
Stefan Hermanowicz et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease
Stefan Hermanowicz et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease
Daniel Weintraub et al.
JAMA NEUROLOGY (2016)
Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia Number Needed to Harm
Donovan T. Maust et al.
JAMA PSYCHIATRY (2015)
Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis
Ketan Dipak Jethwa et al.
BJPSYCH OPEN (2015)
Comparative mortality risks of antipsychotic medications in community-dwelling older adults
T. Gerhard et al.
BRITISH JOURNAL OF PSYCHIATRY (2014)
Treatment of Psychosis and Dementia in Parkinson's Disease
Jennifer G. Goldman et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2014)
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey Cummings et al.
LANCET (2014)
Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
Tiffini Voss et al.
PARKINSONISM & RELATED DISORDERS (2013)
Incidence, Prescription Patterns, and Determinants of Antipsychotic Use in Patients with Parkinson's Disease
Meng-Ting Wang et al.
MOVEMENT DISORDERS (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease
Klaus Seppi et al.
MOVEMENT DISORDERS (2011)
Epidemiology of psychosis in Parkinson's disease
Gilles Fenelon et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
Parkinson's disease psychosis 2010 A review article
Joseph H. Friedman
PARKINSONISM & RELATED DISORDERS (2010)
Neuropsychiatric symptoms in dementia: Importance and treatment considerations
Clive Ballard et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2008)
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group
Bernard Ravina et al.
MOVEMENT DISORDERS (2007)
Antipsychotic use in older adults with Parkinson's disease
Connie Marras et al.
MOVEMENT DISORDERS (2007)
Validity and reliability of assessments of time - Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument
Anders Wimo et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2007)
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist
KE Vanover et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability
A Schrag et al.
PARKINSONISM & RELATED DISORDERS (2006)
Risk of death in elderly users of conventional vs. atypical antipsychotic medications
PS Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Longitudinal outcome of Parkinson's disease patients with psychosis
SA Factor et al.
NEUROLOGY (2003)
Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study
D Aarsland et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2000)
Share Paper
